Open AccessPolypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer
Author(s) -
Cara L. McDermott,
J. Randall Curtis,
Qin Sun,
Catherine R. Fedorenko,
Karma L. Kreizenbeck,
Scott D. Ramsey
Publication year - 2021
Publication title -
journal of oncology pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.548
H-Index - 34
eISSN - 1477-092X
pISSN - 1078-1552
DOI - 10.1177/10781552211006180
Subject(s) - medicine , polypharmacy , pharmacy , odds ratio , cancer , interquartile range , emergency medicine , family medicine
Polypharmacy raises the risk of drug-drug interactions and adverse events among patients with cancer. Most polypharmacy research has focused on adults age 65 or older enrolled in Medicare insurance. To better inform pharmacy practice and cancer care delivery, data are needed on polypharmacy among commercially insured patients with cancer and those younger than 65.